GPT and fatty liver disease: Hepatic steatosis (CAP): Significant reduction in dapagliflozin group (314 → 290 dB/m, P = 0.0424). Liver fibrosis (LSM): Significant reduction in patients with baseline LSM ≥8.0 kPa (14.7 → 11.0 kPa, P = 0.0158).                                  Improved liver enzymes (ALT, AST, GGT) and metabolic markers (HbA1c, HOMA-IR).